Strata Critical Medical, Inc. (SRTA) Q3 2026 earnings results
Strata Critical Medical, Inc. (SRTA) reported Q3 2026 results on Nov 3, 2026, 8:11:10 AM ET: GAAP EPS -$0.09 vs. -$0.01 expected (miss by $0.08); revenue $74.08M vs. $72.67M expected (beat by 1.9%). Outlook: The company reiterated its 2026 guidance of $285-295 million in revenue and $33-35 million in Adjusted EBITDA.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.09 | -$0.01 | Miss by $0.08 |
| Revenue | $74.08M | $72.67M | Beat by 1.9% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 3, 2026, 8:11:10 AM ET. Nexqual published them 104 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 50.3% from $49.30M; GAAP diluted EPS was -$0.09 vs. $0.70.
Stock reaction
The results came out before the market opened. SRTA closed at $4.44 on November 3, 2026, up 3.7% from its $4.28 close on November 2, 2026 before the results. Latest: $5.88 as of 11:53 AM ET, +37.4% since the pre-release close.
Questions and answers
Did Strata Critical Medical, Inc. beat earnings expectations?
No. Strata Critical Medical, Inc. reported GAAP EPS of -$0.09 against an average analyst estimate of -$0.01 (miss by $0.08), and revenue of $74.08M against $72.67M expected (beat by 1.9%).
What were Strata Critical Medical, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.09 and revenue of $74.08M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 50.3% from $49.30M; GAAP diluted EPS was -$0.09 vs. $0.70.
When did Strata Critical Medical, Inc. report Q3 2026 earnings?
Nov 3, 2026, 8:11:10 AM ET, in an SEC 8-K filing (Item 2.02).
How did SRTA stock react to the earnings?
The results came out before the market opened. SRTA closed at $4.44 on November 3, 2026, up 3.7% from its $4.28 close on November 2, 2026 before the results. Latest: $5.88 as of 11:53 AM ET, +37.4% since the pre-release close.
What did Strata Critical Medical, Inc. say about its outlook?
The company reiterated its 2026 guidance of $285-295 million in revenue and $33-35 million in Adjusted EBITDA.
More on SRTA
SRTA stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 3, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:53 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt